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Extent and Consequences of Antibody Formation
Against Adalimumab in PatientsWith Psoriasis
One-Year Follow-up
Stef P. Menting, MD; Paula P. M. van Lümig, MD; Anna-Christa Q. de Vries, MD; Juul M. P. A. van den Reek, MD;
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IMPORTANCE In a previously reported cohort of 29 patients with plaque-type psoriasis
followed up for 24 weeks, clinically relevant antidrug antibody (ADA) to adalimumabwas
frequently found. Long-term data were lacking. We now present the extension of this study:
80 patients followed up for 1 year.
OBJECTIVES To assess the extent of ADA and its clinical consequences after 24 weeks of
adalimumab treatment for psoriasis in a cohort of 80 patients.
DESIGN, SETTING, AND PARTICIPANTS Amulticenter cohort study, performed in the outpatient
dermatology clinic of 2 academic hospitals, included 80 sequential patients receiving
adalimumab therapy for plaque-type psoriasis and had a follow-up of 1 year. Outcome
assessors were not aware of the presence of antibodies to adalimumab or the adalimumab
serum concentration when assessing patients’ Psoriasis Area and Severity Index (PASI), and
personnel analyzing serum samples were blinded to patients’ PASI.
INTERVENTIONS For 80 patients treated with adalimumab for psoriasis, disease severity
(PASI) was assessed, blood samples were collected, and adalimumab and ADA concentrations
was determined at baseline and at weeks 12, 24, and 52.
MAIN OUTCOMES ANDMEASURES Patient PASI and adalimumab and ADA concentrations.
RESULTS Antidrug antibody formed in 49% of patients, before week 24 in 90% of them.
Adalimumab and ADA concentrations, clinical response and ADA concentration, and
adalimumab concentration and clinical response had correlations of −0.872, −0.606, and
0.519, respectively. The adalimumab dose interval was shortened because of lack of efficacy
in 15 patients, 7 with and 8without ADA; improvement in responder status occurred in 1 of 7
and 4 of 8, respectively.
CONCLUSIONS AND RELEVANCE Patients with no ADA formation in the first 24 weeks of
treatment have little chance of it in the following 24 weeks. The presence of ADA is strongly
correlated with adalimumab concentration and greatly influences clinical response. If ADA is
present, dose interval shortening is less useful.
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A dalimumab is a human monoclonal immunoglobulinG1 antibody and tumor necrosis factor antagonist thatis a valuable treatment option for patients with mod-
erate to severe psoriasis seen in clinical practice. As has been
shownforpatientswithCrohndiseaseand rheumatologic con-
ditions, antibodies against adalimumab are associated with
nonresponse and loss of initial response to adalimumab in a
substantial proportion of patients.1-8 This effect has also been
shown for patients with psoriasis. In a cohort study of 29 pa-
tients evaluated for up to 24weeks of treatment, antidrug an-
tibody (ADA) to adalimumab formed in 45%.9 This cohort has
been extended to 80 patients (including the original 29), and
herewepresent1-year follow-updata.Thepurposeof thisstudy
is to assess whether ADAs develop, persist, or reduce after 24
weeks of adalimumab treatment and to determine the clini-
cal consequences.
Methods
Detailed methods and study design have been reported
elsewhere9 and have not changed. Briefly, approached for this
prospective observational cohort study were all consecutive
patients with psoriasis who were naive to adalimumab and
starting treatment with adalimumab for psoriasis at the Aca-
demic Medical Center, Amsterdam, and the Radboud Univer-
sity NijmegenMedical Centre, Nijmegen (both in the Nether-
lands), between September 1, 2008, and July 12, 2012. The
studywas approved by the ethical committee of the participat-
ing hospitals and conducted according to Declaration of Hel-
sinki principles. Patients gavewritten informed consent before
initiation.
Certainbaseline characteristicswere collected.At the time
of evaluation for this report, 80 patients were enrolled. Pa-
tients were treated with adalimumab according to the ma-
nurcturer’s recommendations, with an initial dose of 80 mg
subcutaneously followedby40mgsubcutaneouslyeveryother
week, starting 1 week after the initial dose. Patients could be
treated concomitantlywithmethotrexate fromthe start of the
study. In patients with inadequate response to adalimumab,
concomitantmethotrexate could be started or the dose inter-
val for adalimumab could be reduced to every 7 or 10days (re-
ferred tohereafterasdose interval shortening).Treatmentcould
be terminatedbecauseof nonresponseor adverse events. The
reason for termination of treatment was registered. Deci-
sionsweremadeby the treatingdermatologist anddidnotde-
viate from daily practice. The treating dermatologist was
masked to the antibody status of the patient.
Disease severitywas assessed by the treating physician at
baseline and at weeks 12, 24, and 52 using the Psoriasis Area
andSeverity Index (PASI). Improvementwasmeasured as the
percentageof improvementcomparedwithbaselinePASI.Non-
responders were defined as patients achieving less than 50%
improvement compared with baseline PASI, moderate re-
sponders as those achieving 50% to less than 75% improve-
ment, and good responders as those achieving at least 75%
improvement.10 In case patients switched to adalimumab
therapy from a previous biologic therapy without a washout
period, the PASI before this biologic therapy was used as the
baseline PASI. This was done because otherwise these
patients would seem to be nonresponders despite a good
response to adalimumab therapy.
Blood samples were obtained before initiation of ada-
limumab treatment and at adalimumab serum trough levels
at baseline and at weeks 12, 24, and 52 (just before adminis-
trationofadalimumab,patients receiveda letternotifyingthem
of trough level sampling so this could be timed in relation to
adalimumab administration). The adalimumab levels were
measured by means of enzyme-linked immunosorbent as-
say, and the ADAs were detected with a radioimmunoassay2
(both performed at the Laboratory forMonoclonal Therapeu-
tics,SanquinDiagnosticServices).Theradioimmunoassaydoes
notdetectADAbound toadalimumabandmight thereforeun-
derestimate ADA formation.11,12
The antibody test results were considered positive when
the antibody concentration exceeded 12 AU/mL. Concentra-
tions between 12 and 100AU/mLwere considered lowADA ti-
ters and those above 100AU/mLwere consideredhighADA ti-
ters. IfnodetectableADAswerepresent (<12AU/mL) this result
was categorized as “no ADA.”
Themethodsof statistical analysis areexplained in theear-
lier report.9 In addition,weused theSpearman rank test to cal-
culate the correlation coefficients between the clinical re-
sponse (expressed as ΔPASI), the level of antibodies against
adalimumab, and the adalimumab trough level. To replace
missingbaselinePASIvalues, imputationof themeanwasused.
Formissingvisits,missingadalimumab levels, andmissingan-
tibody titers, the last observation carried forwardmethodwas
used.
Results
Patient Characteristics
This cohort included80patients, 52male and 28 female,with
amean age of 46 years (range, 24-73 years). Themean disease
duration of psoriasis was 23 years (range, 7-51 years), and the
meanPASIatbaselinewas 12 (range, 1.5-27).Threepatientshad
lowbaseline PASI (1.5, 1.7, and 3.8) because theyhad to switch
directly fromefalizumabtoadalimumabwhenefalizumabwas
withdrawn from themarket. One patient had a baseline PASI
of only 3 because shehad switched frometanercept, towhich
her psoriasis responded but her arthritis did not. For these 4
patients, thebaselinePASI frompriorbiologic therapy (9.6,8.6,
18.8, and 11.7) was used as the baseline PASI for this study, as
described in the Methods section.
Sixty-five percent of patients had a PASI of at least 10.0
(excluding the 4 patients just mentioned with replaced PASI
values). Sixty-nine percent had used at least 4 previous sys-
temic treatments for psoriasis; the most frequently used
previous treatments were methotrexate and UV-B (in
95% and 94% of patients, respectively). The mean body
mass index (calculated as weight in kilograms divided by
height in meters squared) was 29.4, and 25% of patients had
a diagnosis of psoriatic arthritis. See the Table for patient
characteristics.
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Clinical Response
All patients reached the week 12 visit, at which point 38
patients (48%) were nonresponders, 16 (20%) were moder-
ate responders, and 26 (32%) were good responders. Of 71
patients who reached the week 24 visit, 24 (30%) were non-
responders, 22 (28%) were moderate responders, and 25
(31%) were good responders. Of the 9 patients who stopped
treatment between the week 12 and 24 visits, 5 discontinued
treatment early because of nonresponse and 3 because of an
adverse event (herpes zoster, pneumonia, and abscess for-
mation in the adalimumab injection site). One patient
stopped treatment because of nonresponse together with an
adverse event (psoriasis palmoplantaris). Fifty-nine patients
(74%) reached the week 52 visit. Fifteen (19%) were nonre-
sponders, 12 (15%) were moderate responders, and 32 were
good responders (40%). Between the week 24 and 52 visits,
12 patients (15%) discontinued treatment; 3 were lost to
follow-up, 8 stopped treatment with adalimumab because
of nonresponse, and 1 stopped treatment because of nonre-
sponse together with an adverse event. Termination of
treatment for nonresponse occurred after a mean duration
of 7.8 months. In total, 21 patients (26%) did not complete 1
year of treatment with adalimumab.
Of the 38 patients who were nonresponders at the week
12 visit, 18 and 9, respectively, remained nonresponders at
weeks 24 and 52. Treatment was terminated early because of
nonresponse in6nonrespondersbetweenweeks 12and24and
in 11 between weeks 24 and 52. Of the 26 patients who were
good responders at the week 12 visit, 18 and 19, respectively,
remained so at weeks 24 and 52. Treatment was terminated
early (before week 52) in 6 good responders: in 1 because of
anadverseevent, in3becauseof lossofeffectivenessover time,
and in 2 because of loss to follow-up.
Clinical Response and Adalimumab Trough Levels
At the study termination (at week 52 or the early termination
[ET] visit), the adalimumab level varied significantly be-
tween nonresponders and moderate responders and be-
tweennonrespondersandgoodresponders (P < .05).Therewas
no significant difference between moderate responders and
good responders.
Figure 1. Adalimumab Trough Level at Study Termination Categorized by
Responder Status
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Adalimumab trough levels are shown by responder status at study termination
(week 52 or early termination visit). Responses were assessed according to the
Psoriasis Area and Severity Index (PASI). Nonresponders were defined as
patients achieving less than 50% improvement compared with baseline,
moderate responders as those achieving 50% to less than 75% improvement,
and good responders as those achieving at least 75% improvement. Outliers
were included in the analyses. Nonresponders attained significantly lower
adalimumab trough levels than good responders.
Table. Patient Characteristics
Characteristic
Total
(N = 80)
Patients With ADA
(n = 39)
Patients Without ADA
(n = 41)
Age, mean (SD), y 46 (13) 46 (12) 46 (13)
Male, sex, No. (%) 52 (65) 26 (67) 26 (63)
Disease duration, mean (SD), y 23 (11) 22 (11) 25 (12)
PASI baseline, mean (SD) 13 (5) 13 (6) 12 (5)
BMI, mean (SD) 29 (6) 30 (5) 29 (7)
PsA, No. (%) 20 (25) 10 (26) 10 (24)
Concomitant methotrexate from week 0, No.
(%)
8 (10) 3 (8) 5 (12)
Previous systemic treatment, No. (%)
Methotrexate 76 (95) 37 (95) 39 (95)
Cyclosporine 55 (69) 29 (74) 26 (63)
Fumaric acid esters 23 (29) 13 (33) 10 (24)
UV-B 75 (94) 36 (92) 39 (95)
Psoralen–UV-A 45 (56) 23 (59) 22 (54)
Etanercept 54 (68) 29 (74) 25 (61)
Infliximab 3 (4) 1 (3) 2 (5)
Efalizumab 16 (20) 11 (28) 5 (12)
Adalimumab 0 0 0
Ustekinumab 0 0 0
No. of previous treatments, mean (SD) 4 (1) 5 (1) 4 (1)
Abbreviations: ADA, antidrug
antibody; BMI, bodymass index
(calculated as weight in kilograms
divided by height in meters squared);
PASI, the Psoriasis Area and Severity
Index; PsA, psoriatic arthritis.
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Adalimumab trough levels ranged from 0.0 to 20.9 mg/L
for nonresponders, 1.1 to 16.5 mg/L for moderate respond-
ers, and 0.1 to 29.2 mg/L for good responders (Figure 1).
The Spearman rank correlation coefficient was calculated
and showed a moderately strong correlation coefficient of
0.519.
Concentrations of Antibodies to Adalimumab
During 52weeks of follow-up, ADAswere detected in 39 of 80
patients (49%). Antidrug antibody formationoccurred for the
first time beforeweek 12 in 18 patients, betweenweeks 12 and
24 in 17, andbetweenweeks24and52 in4.At theweek 12visit,
8patientshada lowADAtiter (13-34AU/mL), 10hadahighADA
titer (195-7300 AU/mL), 53 had no ADA, and 9 had a missing
value. In 16 of the 18 patientswith ADA, the ADA titer atweek
24 or ET had risen. At the week 24 visit, 20 patients had a low
ADA titer (13-96 AU/mL), 9 had a high titer (1220-55700 AU/
mL), 37 had no ADA, and 5 had a missing value. In 5 patients
with ADA at week 24 (range, 14-35 AU/mL), ADA had disap-
pearedatweek52 (noexplanation found). In the remainingpa-
tients with ADA at week 24, ADA had increased or remained
the same or patients had undergone ET. At the week 52 visit,
19 had a low ADA titer (13-96 AU/mL), 1 had a high ADA titer
(68 333 AU/mL), 37 had no ADA, and 2 had a missing value
(Figure 2).
All 18 patientswithADAatweek 12 hadADAatweek 24or
underwent ET before week 24. All patients with low ADA ti-
ters continued to have low or high ADA titers at week 24. Of
the31patientswithADAat theweek24visit, 4 showednoADA
atweek 52 (all had lowADA titers atweek 24; range, 14-35AU/
mL). The remaining 27 patients still showed ADA at week 52
or underwent ET.
Adalimumab Trough Level and Antibodies to Adalimumab
Adalimumabtrough level rangedfromundetectable to31mg/L.
At week 12, the median adalimumab level in patients receiv-
ing40mgof adalimumabeveryotherweekwas8mg/L (range,
0-20). Atweeks 24 and52, themedian (range) levelswere 5 (0-
31) and7 (0-19)mg/L, respectively.Figure2showsdifferentme-
dian adalimumab trough levels by ADA status and week. For
weeks 12, 24, and 52, respectively, 9, 5, and 2 patients had no
serum samples obtained. At week 52, in 5 patients it was not
certain that serum samples were obtained at a trough level;
these 5 measurements were excluded from analysis.
At termination of the study (week 52 or the ET visit), the
adalimumab level did vary significantly among patients with
no, low, and high ADA, with a median (range) of 10.5 (2.0-
29.2), 2.0 (0.1-6.5), and 0.0 (0.0-0.1) mg/L, respectively
(Figure 2). The Spearman rank correlation coefficientwas cal-
culated and showed a very strong negative correlation coeffi-
cient of −0.872 between adalimumab level and ADA concen-
tration.
AdalimumabDose Interval Shortening
Twopatientshadthedosing interval shortenedatweek12,both
becauseofnonresponse.OnepatienthadnoADAandchanged
into a good responder. One patient was receiving oral predni-
sone for asthma togetherwith a shorteneddose interval. This
patienthadhighADA(474AU/mL)atweek 12andchanged into
a moderate responder, with low ADA (25 AU/mL) at week 52.
Seven patients had the dosing interval shortened between
weeks 12 and 24, because of nonresponse in 5 and moderate
response in 2. Three of the nonresponders had high ADA ti-
ters before dose interval shortening and remained nonre-
sponders.TwopatientswithoutADAbeforedose interval short-
ening improved in responder status, and 2 without ADA
remained at the same level of responder status. Six patients
had the dosing interval shortened between weeks 24 and 52,
because of nonresponse and moderate response in 3 each.
Three of the patients had ADA before dose interval shorten-
ing and did not improve responder status. Three of the pa-
tients had no ADA; responder status did not improve in 2 and
did improve in 1 (Figure 3). There was no significant differ-
ence in adalimumab trough level between patients who un-
derwent dose interval shortening and those who did not.
Figure 2. Median Adalimumab Trough Level by Antidrug
Antibody (ADA) Status
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The 3 lines represent adalimumab trough levels by ADA group at weeks 12, 24,
and 52. Antidrug antibody titers less than 12 AU/mL are considered no ADA;
titers between 12 and 100 AU/mL, low ADA; and titers above 100 AU/mL, high
ADA. Patients with low ADA titers or no ADA attained detectable adalimumab
trough levels, but patients with high ADA titers did not.
Figure 3. Flowchart of PatientsWith AdalimumabDose
Interval Shortening
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This flowchart shows patients in whom the adalimumab dose interval was
shortened and the effect on clinical response. The antidrug antibody status
seems to influence the effect of dose interval shortening; in other words, dose
interval shortening seems less useful if antidrug antibodies to adalimumab are
present.
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Concomitant Use ofMethotrexate
Eight patients received concomitant methotrexate therapy
from week 0. Among these 8 patients, (low) ADA developed
in 3 (at weeks 12, 24, and 52). No methotrexate-treated pa-
tientshadhighADAtiters, and5hadnoADAformation.Metho-
trexate dosage ranged from 2.5 to 20 mg/wk. Methotrexate
therapy was initiated in 1 patient at week 12. Responder sta-
tus improved in this patient who did not have ADA forma-
tion. At week 24, methotrexate therapy was initiated in 3 pa-
tients. Responder status improved in 2. In 1 of 2 patients who
had ADA before concomitant methotrexate therapy, ADA ti-
ters went from high to low.
In 2 patients, the dose interval was shortened during the
same time interval methotrexate was added. One patient re-
mained amoderate responder, butADA titerswent from2950
to87AU/mL; theotherpatienthadnoADAandwent frombeing
a nonresponder to a good responder. There was no signifi-
cant difference in adalimumab trough level between patients
whowere concomitantly treatedwithmethotrexate andwho
were not.
Clinical Response and Concentrations
of Antibodies to Adalimumab
Among the 32 good responders at theweek 52 visit, 27 had no
ADA, 5 had lowADA (range, 16-73 AU/mL), and none had high
ADA.Among the 13moderate responders, 7hadnoADA,6had
lowADA(range, 13-96AU/mL), andnonehadhighADA.Among
the 14 nonresponders, 4 had no ADA, 9 had low ADA titers
(range, 13-62 AU/mL), and 1 had a high ADA titer (68 333 AU/
mL). In total, 14 patients underwent ET because of nonre-
sponse, 5 betweenweek 12 and 24 and9betweenweek 24 and
52. Two of them had no ADA, 3 had low ADA, and 9 had high
ADA. Figure 4 shows the responder status by ADA titer at the
terminationof the study (week 52or ETvisit,whichever came
first).AllpatientswithhighADAatweek12, 24,or52orETwere
nonresponders at that time. Not all nonresponders had high
ADA. At the termination of the study (at week 52 or ET visit,
whichever came first), the ADA concentration varied signifi-
cantly betweennonresponders andmoderate responders and
betweennonresponders andgood responders (P < .05). There
was no significant difference between moderate responders
and good responders. Themedian (range) in AU/mLwas 0 (0-
73), 0 (0-31), and 39 (0-68333) for good,moderate, and nonre-
sponders, respectively. The Spearman rank correlation coef-
ficientwascalculatedandshowedamoderatelystrongnegative
correlation coefficient of −0.606.
Discussion
The purpose of our studywas to assess whether the extent of
antibody formation against adalimumab in the treatment of
psoriasis vulgaris increases, persists, or decreases after 24
weeks of adalimumab treatment and to determine the clini-
cal consequences of such changes. In conclusion, our find-
ings show that the biggest chance of first-time ADA develop-
ment is in the first 24weeksof treatment (35 vs4patients) and
further support thenotion that thepresenceofADA is strongly
correlated with adalimumab level (correlation coefficient,
−0.872)andgreatly influencesclinical response (correlationco-
efficient, −0.606), also after 24 weeks of treatment. Dose in-
terval shortening might be useful if no ADAs are present, but
it seems less useful if they are present.
In the previous study, 13 of 29 patients (45%) had ADA
formation,9 comparedwith39of80 (49%) in thecurrent study.
In studies performed in patients with rheumatoid arthritis
treated with adalimumab, these percentages are lower. Bar-
telds et al13 showed in a 3-year follow-up study that 28%of pa-
tients had ADA formation. Many patients (74%) in that study
usedconcomitantmethotrexate, butpatientswithADAforma-
tion less oftenhad concomitantMTX.Moreover, in other stud-
ies, the concomitant use of immunosuppressants reduces the
frequency of antibody formation in response to biologic
therapy,14,15 and a favorable effect of concomitant methotrex-
ate on reducing antibody formation has been postulated. In a
letter by Krieckaert et al,16 it was reported that methotrexate
seems to reduce ADA formation efficiently and in a dose-
dependentmanner.
Methotrexate treatment did not reduceADA formation in
our study; 3of8patients (38%)whoreceivedmethotrexatehad
(low)ADA. Thismight be due to the lowdose ofmethotrexate
used by these 3 patients (2.5, 10, and 10mg/wk). The number
of patients using concomitantmethotrexate in our studywas
limited, so these data should be interpreted with caution. Of
the patients in our cohort not receiving concomitant metho-
trexate, 50% (36 of 72 patients) had ADA formation. Bartelds
et al13 found the same,withADA formation in 50%of patients
(35of 70)not receiving concomitantmethotrexate.Of their pa-
tients receivingconcomitantmethotrexate,only20%(41of202)
hadADA formation,which further supports the role ofmetho-
trexate in reducing immunogenicity, instead of, for example,
disease (psoriasis)–related factors. The treatmentdoseof ada-
limumab is similar for psoriasis and rheumatoid arthritis. A
Figure 4. Responder Status by Antidrug Antibody (ADA) to Adalimumab
Titer at Study Termination
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Antidrug antibody titers less than 12 AU/mL are considered no ADA; titers
between 12 and 100 AU/mL, low ADA; and titers above 100 AU/mL, high ADA.
Responder status was based on improvement in the Psoriasis Area and Severity
Index, relative to baseline (see Methods). This figure shows that patients with
high ADA titers are always nonresponders. (Study termination was at week 52
or the early termination visit.)
Research Original Investigation Antibody Formation Against Adalimumab in Psoriasis
134 JAMADermatology February 2014 Volume 150, Number 2 jamadermatology.com
Downloaded From: http://jamanetwork.com/pdfaccess.ashx?url=/data/journals/derm/929764/ by a Radboud University Nijmegen User  on 03/13/2017
Copyright 2014 American Medical Association. All rights reserved.
study by Karmiris et al17 included patients treated with
adalimumab for Crohn disease; only 9.2% had ADA forma-
tion. This finding may be explained by disease-related fac-
tors or the fact that most of these patients (75% of 168) were
treated with an initial dose of 160 mg for the first week and
80 mg for the next, instead of 80 mg as an initial dose and
40 mg for the next week, which is common practice in pso-
riasis treatment.
Obtaining a sufficient adalimumab trough level does not
imply good clinical improvement. In our cohort, some pa-
tients obtained a good adalimumab trough level but no suffi-
cient clinical improvement. Is it is not clearwhat factors other
than antibody formationmay impair treatment. Ahypothesis
could be that tumor necrosis factormaynot be the leading in-
flammatory agent in these patients.
Adalimumabwasadministeredeveryotherweek,anddose
interval shortening to every 7 or 10 days could be applied in
case of nonefficacy. As shown by our results, dose interval
shorteningmight beuseful if noADAs are present. Thismight
be explained by the fact that ADAs result in functional neu-
tralization of adalimumab.12 However, given the limited size
of this specific populationwithin this study, thesedata should
be interpretedwith caution. Leonardi et al18 observed that pa-
tientsweighing 102 kgor less orwith adiseasedurationof less
than 8.3 years were most likely to benefit from dose escala-
tion. In the 15 patients with dose escalation presented here,
we did not observe this.
In the group of patients with ADA, 90% had ADA forma-
tion for the first time before week 24. This is in line with the
findings by Bartelds et al,13 inwhich 67%of patients had ADA
formationduring the first 28weeks. This implies thatmostpa-
tients who have ADA formation will do so during the first 24
weeks of treatment.
As reported in theprevious study, the response rate in the
current study is surprisingly lower than those reported in 3
phase 3 trials,19-21 with PASI improvement of at least 75% at
week 12 or 16 in 53%, 71%, and 80%of patients. In our current
study, 33%of patients showedat least 75% improvement rela-
tive to baseline, in accordance with a study by van Lümig et
al,22 in which 34% of patients showed at least 75% improve-
ment at week 12; both of these studies present “real-world
data,” which might explain the difference in response rates
compared with the phase 3 trials.
Nine patients continued adalimumab treatment until at
least week 52 despite remaining nonresponders. Six of them
hadPASI improvementof 32%to43%atweek52andwerecon-
tent with this result. Eight of 9 patients had been previously
treated with etanercept. In these cases, treatment with ada-
limumabmayalsobe continuedbecauseof lackof other treat-
ment options. Infliximab would have to be administered in-
travenously in a daycare setting, and experience with
ustekinumab was still small.
In this study, we have also further endorsed the strong
negative correlation between ADA formation and adalim-
umab serum trough levels, with a correlation coefficient of
−0.872. The higher the ADA titer, the lower the adalimumab
trough level. In a different study,12 itwas shown that virtually
all ADAs are neutralizing and that the ADAs are highly spe-
cific foradalimumab, formingsmall immunecomplexes, in this
wayneutralizing thedrug. It hasbeensuggested thatADAmay
lead to thromboembolic events23 or a type III hypersensitiv-
ity reaction,12 which has not been observed in this cohort.
This study has some limitations. Because of the limited
number of patients experiencing dose interval shortening
and the limited number using concomitant methotrexate,
the influence of these interventions on antibody formation
and effectiveness should be further investigated in a larger
cohort.
The last observation carried forwardmethodwas used to
replacemissingvalues for adalimumab levels andantibody ti-
ters. Thismay have led to underestimation of ADA formation
and overestimation of drug levels.
The antibody assay used in this study (a radioimmunoas-
say) is the same used in the studies by Bartelds et al1,2,13 and
Krieckaert et al16 but different from the bridging enzyme-
linked immunosorbent assay used by Vermeire et al15 and
Karmiris et al.17 The latter is more sensitive to drug interfer-
ence and does not detect immunoglobulin G4 ADA,11 making
comparison between these studies less reliable. The influ-
ence of methotrexate on ADA formation needs further re-
search, as well as the influence of dose interval shortening in
ADA-positive and ADA-negative patients.
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Invited Commentary
PRACTICEGAPS
Preventing and Detecting Antibodies to Anti–Tumor Necrosis
Factor Agents
Gaps in Practice or in Evidence?
Kristina Callis Duffin, MD, MS
Although anti–tumor necrosis factor (TNF) agents are con-
sidered highly effective therapies for psoriasis, treatment
failure is common. As highlighted in the study by Menting
et al,1 primary failure is more frequent in the “real-world”
setting compared with ran-
domized clinical trials with
adalimumab and is associ-
ated with formation of anti-
drug antibodies (ADAs) and low serum drug levels. This
article further highlights the high frequency of ADA forma-
tion (50%) in patients not receiving concomitant methotrex-
ate. These issues raise 2 questions: (1) should adalimumab
be prescribed with methotrexate at the outset and (2)
should ADA and trough drug levels be drawn when patients
fail to respond to adalimumab to aid in the decision to esca-
late dose or switch therapy?
Therearenoconsensusguidelines that recommendmetho-
trexate be routinely prescribed with adalimumab to prevent
ADA formationand thereforeprevent treatment failure. There
have just not been enough data to support this when treat-
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